Viridian Therapeutics’ stock price surged over 20% following the announcement of positive Phase III trial results for veligrotug, an investigational treatment for chronic thyroid eye disease (TED). The THRIVE-2 study met all primary and secondary endpoints, demonstrating significant improvements in proptosis (eye bulging) and diplopia (double vision) with a favorable safety profile.
Table Content:
The global THRIVE-2 (NCT05176639) Phase III study evaluated the efficacy and safety of intravenously administered veligrotug, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic TED. The data revealed a 56% proptosis responder rate (PRR), signifying a meaningful reduction in proptosis, with a mean reduction of 2.34mm. Furthermore, veligrotug achieved a 56% diplopia response rate, with 32% of patients experiencing complete resolution of double vision compared to only 14% in the placebo group. These results significantly exceeded expectations and underscore the potential of veligrotug to address the debilitating symptoms of TED.
Understanding the Impact of Thyroid Eye Disease
Thyroid eye disease, also known as Graves’ ophthalmopathy, is an autoimmune disorder characterized by inflammation and swelling of the muscles and tissues surrounding the eyes. This inflammation can lead to a range of symptoms, including proptosis, diplopia, pain, redness, and vision impairment. TED significantly impacts patients’ quality of life, affecting their physical appearance, visual function, and emotional well-being. Current treatment options for chronic TED are limited, highlighting the unmet need for effective therapies.
Veligrotug: A Potential Game-Changer for TED Treatment
Steve Mahoney, President and CEO of Viridian Therapeutics, expressed enthusiasm for the THRIVE-2 results, stating that they “confirm the potential of veligrotug to be the treatment of choice for all forms of active and chronic TED.” The robust and consistent data from THRIVE-2, mirroring the positive outcomes observed in the earlier THRIVE-1 trial, indicate that veligrotug offers a rapid and significant improvement in key symptoms affecting TED patients. Importantly, veligrotug is the first product candidate to demonstrate a positive diplopia response and resolution rate in a global Phase III chronic TED study.
Addressing the Unmet Needs in Chronic TED
Tony Casciano, Chief Commercial Officer for Viridian Therapeutics, highlighted the significance of the diplopia response observed in the study, emphasizing the potential for veligrotug to become the only approved therapy with data specifically addressing chronic TED patients. The comprehensive clinical program for veligrotug, the largest conducted in TED to date, positions it for advantageous market access and expanded utilization in patients who currently lack effective treatment options. Viridian Therapeutics is conducting two additional trials, REVEAL-1 (NCT06625411) and REVEAL-2 (NCT06625398), investigating veligrotug in active and chronic TED, respectively, with top-line results expected in the first half of 2026.
Conclusion: A Promising Future for Veligrotug and TED Patients
The positive results from the THRIVE-2 trial mark a significant advancement in the treatment of chronic TED. Veligrotug’s demonstrated efficacy in reducing proptosis and resolving diplopia, coupled with its favorable safety profile, positions it as a potential game-changer for patients living with this debilitating condition. The upcoming REVEAL trials will further elucidate the potential of veligrotug and solidify its role in addressing the unmet needs of individuals affected by TED. The strong clinical data and market potential of veligrotug have fueled investor confidence, driving Viridian Therapeutics’ stock to new heights.
